Company Overview and News

 
Harwood seeks to capitalise on rental boom with £175m float

2018-08-12 telegraph.co.uk
Harwood Capital, the fund run by JO Hambro founder Christopher Mills, is planning a £175m float of part of its property arm to capitalise on demand for rented homes.
BTT

 
Nine promises to safeguard Fairfax journalism in $4.2 billion tie-up

2018-07-26 theage.com.au
The journalistic traditions of The Sydney Morning Herald and The Age will be upheld under its new ownership, Nine Entertainment chief executive Hugh Marks has insisted after his company struck a $4.2 billion deal to gain control of Fairfax Media.
WANHY SWM BTT WANHF

 
Nine promises to safeguard Fairfax journalism in $4.2 billion tie-up

2018-07-26 smh.com.au
The journalistic traditions of The Sydney Morning Herald and The Age will be upheld under its new ownership, Nine Entertainment chief executive Hugh Marks has insisted after his company struck a $4.2 billion deal to gain control of Fairfax Media.
WANHY SWM BTT WANHF

2
Top companies 'failing' on gender pay gap face investor revolt

2018-07-23 theage.com.au
Investors could take stronger action to force listed companies to address the gender pay gap – including protest votes against re-election of board members and executive remuneration – according to the Australasian Centre for Corporate Responsibility (ACCR) which found that more than one quarter of ASX100 companies did not have a remuneration policy that explicitly covered gender pay equity.
JBHHY RMYHY JHIUF EVN MDBPF LGTHY SYDDF CIM SYD QUB GMG CAHPF RMSYF HNORY JHX TPPTY TPM JHX JBH MDBKY MPL TPGTF RHC HVN LGTHF BTT

2
Top companies 'failing' on gender pay gap face investor revolt

2018-07-23 smh.com.au
Investors could take stronger action to force listed companies to address the gender pay gap – including protest votes against re-election of board members and executive remuneration – according to the Australasian Centre for Corporate Responsibility (ACCR) which found that more than one quarter of ASX100 companies did not have a remuneration policy that explicitly covered gender pay equity.
JBHHY RMYHY JHIUF EVN MDBPF LGTHY SYDDF CIM SYD QUB GMG CAHPF RMSYF HNORY JHX TPPTY TPM JHX JBH MDBKY MPL TPGTF RHC HVN LGTHF BTT

28
Get active or get delisted, responsible investment group warns funds

2018-04-01 theage.com.au
Super funds and fund managers keen to spruik their responsible investment credentials will need to work harder to avoid being delisted by the Principles for Responsible Investment, with the London-based group saying it will push its 1900-plus members to be more active on issues like climate change, human rights and corruption.
RIO RIO RTPPF RIO RTNTF MS BTT

28
Get active or get delisted, responsible investment group warns funds

2018-04-01 smh.com.au
Super funds and fund managers keen to spruik their responsible investment credentials will need to work harder to avoid being delisted by the Principles for Responsible Investment, with the London-based group saying it will push its 1900-plus members to be more active on issues like climate change, human rights and corruption.
RIO RIO RTPPF RIO RTNTF MS BTT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:BTT / BT INVESTMENT MANAGEMENT LIMITED on message board site Silicon Investor.

Bitterroot Res. (V.BTT) Bitterroot Res. (V.BTT) Bitterroot Res. (V.BTT)